| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Spyre Therapeutics, Inc. (SYRE) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 28 sells. SYRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 597.5K | $52.79M | -15,000 | |
| Other | 313.3K | $27.68M | -8,333 | |
| Other | 140.0K | $12.37M | - | |
| CFO | 103.7K | $9.16M | -7,500 | |
| Dir | 8.0K | $709.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Sloan Sheldon | Chief Medical Officer | Sale+OE | 8,333 | $75.00 | $624,975.00 | -100% | - | - | |
| Jun 1, 2026 | Burrows Scott L74 | Chief Financial Officer | Sale+OE | 7,500 | $71.06 | $532,936.98 | -2.4% | - | - | |
| Jun 1, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $70.43 | $1,056,486.02 | -0.8% | - | - | |
| May 1, 2026 | Sloan Sheldon | Chief Medical Officer | Sale+OE | 78,333 | $71.50 | $5,600,701.16 | -35.1% | - | - | |
| May 1, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $71.37 | $1,070,507.00 | -0.4% | - | - | |
| May 1, 2026 | Burrows Scott L74 | Chief Financial Officer | Sale+OE | 12,500 | $71.37 | $892,125.00 | -11.3% | - | - | |
| Apr 1, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $49.33 | $739,912.32 | -1.2% | - | - | |
| Apr 1, 2026 | Burrows Scott L74 | Chief Financial Officer | Sale+OE | 7,500 | $49.34 | $370,076.00 | -3.7% | - | - | |
| Apr 1, 2026 | Sloan Sheldon | Chief Medical Officer | Sale+OE | 7,958 | $50.00 | $397,900.00 | -100% | - | - | |
| Mar 3, 2026 | Burrows Scott L74 | Chief Financial Officer | Sale+OE | 2,500 | $40.65 | $101,620.00 | -1.3% | +83.6% | - |